Last reviewed · How we verify
HRS9531 Tablet
HRS9531 Tablet's mechanism of action is not publicly available.
At a glance
| Generic name | HRS9531 Tablet |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action of HRS9531 Tablet.
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects (PHASE1)
- Efficacy and Safety of HRS9531 Tablet in Obese Subjects (PHASE2)
- A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects (PHASE1)
- Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects (PHASE1)
- Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS9531 Tablet CI brief — competitive landscape report
- HRS9531 Tablet updates RSS · CI watch RSS
- Fujian Shengdi Pharmaceutical Co., Ltd. portfolio CI